A Banner Year for Biosimilars: The 19 FDA Approvals From 2024
The 19 FDA Approvals in 2024 (Chronologically) Simlandi (adalimumab-ryvk) Jubbonti (denosumab-bddz) Wyost (denosumab-bddz) Tyenne (tocilizumab-aazg) Selarsdi (ustekinumab-aekn) Hercessi (trastuzumab-strf) Opuviz (aflibercept-yszy) Yesafili (aflibercept- …